Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.69 |
| ▸ | NAAA | Q02083 | 1/20 | 0.65 |
| ▸ | FAAH | O00519 | 4/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.55 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889128 | 1.00 | CASP2 (0.69) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL889190 | 1.00 | CASP2 (0.69) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL889146 | 1.00 | CASP2 (0.69) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL889142 | 1.00 | CASP2 (0.69) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL889144 | 1.00 | CASP2 (0.69) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL889185 | 1.00 | CASP2 (0.69) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL22923666 | 0.98 | CASP2 (0.66) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL13407575 | 0.92 | CASP2 (0.57) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL15693100 | 0.92 | CASP2 (0.55) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL13375747 | 0.91 | CASP2 (0.67) | CASP2NAAAFAAHEPHX1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362283-A1 | NISIN-BASED COMPOUNDS AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | UNIVERSITEIT UTRECHT HOLDING B.V. (NL) | 2017-12-21 | — | — | US | disclosed |
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | FCGRT, MYD88, C3AR1 | CASP2 2840/4885NAAA 789/4885FAAH 858/4885 |
| US-20170362283-A1 | NISIN-BASED COMPOUNDS AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | NISCH, VIP, NGLY1 | CASP2 865/4885NAAA 35/4885FAAH 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.